Ovarian Cancer Therapy Market to Reach $2.9 Billion by 2022

Press Releases

Ovarian Cancer Therapy Market to Reach $2.9 Billion by 2022

April 12, 2018

WELLESLEY, Mass., April 12, 2018– An aging population, increased healthcare spending, regulatory factors and technological advancements are conspiring to drive growth of the worldwide market for ovarian cancer therapies and diagnostics, according to a report by BCC Research. Growth will be strong around the world, but particularly robust in the Asia-Pacific region.

The global market is expected to see a compound annual growth rate (CAGR) of 7.1% through 2022, when it could be worth $2.9 billion, according to the report Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022.

While the industry is experiencing tremendous growth, there is an increasing need for new and innovative technologies.

Major players in the market include Roche Holding, Novartis, Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals, Pfizer, Eli Lilly, Astra Zeneca, Merck and AbbVie. Roche was the market leader, with a 28% share of the ovarian cancer therapy industry.

Research Highlights

  • The Asia-Pacific region is the fastest-growing area, with a CAGR of 9.1% expected through 2022. By size, the leading market is North America, which has an estimated 2022 value of $1.2 billion.
  • The market is dominated by therapies for epithelial ovarian tumors, which expect a CAGR through 2022 of 7.1% and a value of $2.6 billion. Growth will be greatest in therapies for primary peritoneal carcinoma, which expects a CAGR through the period of 8.8%.
  • Family history, genetic mutation, age, previous health conditions and smoking are major risk factors for ovarian cancer. The cancer mainly develops in women aged 63 or older. Ovarian cancer accounts for an estimated 239,000 new cases and 152,000 deaths worldwide each year. The highest rates of new cases and deaths are in Eastern and Central Europe.

“In developed countries, ovarian cancer still remains the most lethal of all gynaecologic malignancies,” said Robert G. Hunter, BCC Research senior editor, healthcare. “One of the reasons for the high fatality rate is that more than 70% of women with ovarian cancer are diagnosed with advanced disease. Early detection of ovarian cancer represents the best hope for increased long-term survival rates and long-term disease control, but to date, researchers are still trying to improve ovarian cancer diagnostics.”

Leading Companies May Face an Upcoming Patent Cliff Thanks to Biosimilars

The therapeutic drug industry’s patent cliff began in earnest in 2011 and peaked in 2012 as some major well-known drugs faced patent expirations and increased competition in the United States. A second cliff may be looming, the report notes, as top biologic blockbusters face challenges from biosimilars. Global sales at risk from patent expiration totalled $52 million in 2016 but are expected to rise to $194 million by 2022. The report notes that 24 drugs are scheduled to lose patent protection this year, followed by an additional 19 in 2019.

 

Editors/reporters requesting analyst interviews should contact steven.cumming@bccresearch.com.

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022( HLC143B )
Publish Date: Apr 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.